Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.